Injectable Drug Delivery Market Set for Healthy Growth

Led by the strong growth of biotechnology drugs requiring novel delivery technologies, the injectable/implantable drug delivery market is steadily growing, says a new market research study by Kalorama Information (New York, NY, USA), an independent market research company on medical markets.

The market is dominated by implantable, sustained-release, and targeted-injection drug delivery systems with manufacturer revenues of approximately US$7.3 billion in 2006, an increase of 6.3% over 2002 sales. Growth continues to be fueled by the introduction of biologic therapies, including blood modifiers and insulin products, with the sector projected to reach $9 billion by 2010. An expanding drug delivery marketplace, increasing consumer awareness, and growing focus on healthcare worker safety could help drive additional demand for needle-free systems, with revenues expected to reach $3 billion by 2010.

"The development of better delivery systems in conjunction with the discovery of novel pharmacological compounds will lead to significant improvements in drug delivery,” said report author Mary Anne Crandall. "This is a dynamic market expected to increase at break-neck speed during the forecast period. Significant revenue increases are anticipated particularly in the needle-free delivery of injectable medications, especially in the vaccine arena.”

Implantable technologies have been successfully utilized in administering anti-cancer therapeutics as well as the administration of high drug doses in traditionally inaccessible areas, such as the central nervous system, bone tissue, and beyond the blood–retinal barrier.


Related Links:
Kalorama Information